EGFR and non-small cell lung carcinoma: In a retrospective NSCLC cohort (438 individuals, in which 69 were treated with immunotherapy, 258 were untreated, and a collection of EGFR and K-ras genotyped tumors), high coexpression of CMTM6 and PD-L1, particularly in the stroma (e.g., macrophages), predicted the outcomes of PD-1 blockade immunotherapy (Zugazagoitia et al., 2019).